VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial VTP-1000 was well-tolerated with no ...
Nurix Therapeutics, Inc. has announced a webcast conference call scheduled for June 12, 2025, at 8:00 a.m. ET to discuss new data from its ongoing Phase 1 clinical trial of bexobrutideg (NX-5948), ...
Janux provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr, following Phase 1a completion and ...
Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients Preliminary results are encouraging with deep ...
Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026 WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research ...
SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more ...
PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics today announced the launch of a Phase 1, dose-escalating trial of STM-01, Secretome’s neonatal cardiac progenitor cell (nCPC) product, for the ...
Revolution Medicines (RVMD) on Wednesday announced clinical updates from its daraxonrasib Phase 1 clinical trials. The data focuses on new daraxonrasib data in patients with metastatic pancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback